These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86 related articles for article (PubMed ID: 6227628)
1. Serum levels of type I and III procollagen fragments in Paget's disease of bone. Simon LS; Krane SM; Wortman PD; Krane IM; Kovitz KL J Clin Endocrinol Metab; 1984 Jan; 58(1):110-20. PubMed ID: 6227628 [TBL] [Abstract][Full Text] [Related]
2. Procollagen-III peptide serum levels in Paget's disease of the bone. Wilder-Smith CH; Raue F; Holz-Gottswinter G; Ziegler R Klin Wochenschr; 1987 Feb; 65(4):174-8. PubMed ID: 3104661 [TBL] [Abstract][Full Text] [Related]
3. Paradoxical acute hypercalcemic effect of salmon calcitonin in patients having Paget's disease of bone after treatment with dichloromethylene diphosphonate. Delmas PD; Chapuy MC; Meunier PJ Horm Metab Res; 1984 May; 16(5):258-61. PubMed ID: 6234216 [TBL] [Abstract][Full Text] [Related]
4. Changes in serum levels of type I and III procollagen extension peptides during infusion of human parathyroid hormone fragment (1-34). Simon LS; Slovik DM; Neer RM; Krane SM J Bone Miner Res; 1988 Apr; 3(2):241-6. PubMed ID: 3213618 [TBL] [Abstract][Full Text] [Related]
5. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease. Alvarez L; Guañabens N; Peris P; Monegal A; Bedini JL; Deulofeu R; Martinez de Osaba MJ; Muñoz-Gomez J; Rivera-Fillat F; Ballesta AM J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468 [TBL] [Abstract][Full Text] [Related]
6. Sequential treatment of Paget's disease with human calcitonin and dichloromethylene diphosphonate (Cl2MDP). Adami S; Guarrera G; Salvagno G; Spiazzi G; Marini G; Rosini S; Lo Cascio V Metab Bone Dis Relat Res; 1984; 5(6):265-7. PubMed ID: 6238218 [TBL] [Abstract][Full Text] [Related]
8. Procollagen type I carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with Iliac bone formation rates and comparison with total alkaline phosphatase. Parfitt AM; Simon LS; Villanueva AR; Krane SM J Bone Miner Res; 1987 Oct; 2(5):427-36. PubMed ID: 3455625 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of circulating type I procollagen propeptides in patients with Paget's disease of bone. Bonnin MR; Moragues C; Nolla JM; Lirón FJ; Roig-Escofet D; Navarro MA Clin Chem Lab Med; 1998 Jan; 36(1):53-5. PubMed ID: 9594087 [TBL] [Abstract][Full Text] [Related]
10. Radioimmunoassay of procollagen in serum of patients with Paget's disease of bone. Taubman MB; Kammerman S; Goldberg B Proc Soc Exp Biol Med; 1976 Jun; 152(2):284-7. PubMed ID: 819938 [TBL] [Abstract][Full Text] [Related]
11. [Short-term biological effects of synthetic salmon calcitonin in Paget's disease. Influence of posology]. Chapuy MC; Meunier P; Terrier M; David L; Vignon G Pathol Biol (Paris); 1975 May; 23(5):349-59. PubMed ID: 172838 [TBL] [Abstract][Full Text] [Related]
12. Sustained biochemical effects of short treatment of Paget's disease of bone with dichloromethylene diphosphonate. Chapuy MC; Charhon SA; Meunier PJ Metab Bone Dis Relat Res; 1983; 4(6):325-8. PubMed ID: 6229683 [TBL] [Abstract][Full Text] [Related]
13. Paget's disease of the bone: observations after cessation of long-term synthetic salmon calcitonin treatment. Avramides A; Flores A; DeRose J; Wallach S J Clin Endocrinol Metab; 1976 Mar; 42(3):459-63. PubMed ID: 1254686 [TBL] [Abstract][Full Text] [Related]
14. Effects of disodium dichloromethylene diphosphonate (CL2MDP) on Paget's disease of bone. Meunier PJ; Chapuy MC; Alexandre C; Bressot C; Vignon E; Trechsel U; Mathieu L; Edouard C Adv Exp Med Biol; 1980; 128():299-309. PubMed ID: 6448538 [No Abstract] [Full Text] [Related]
15. Long-term treatment of Paget's disease of bone with salmon calcitonin. Sturtridge WC; Harrison JE; Wilson DR Can Med Assoc J; 1977 Nov; 117(9):1031-4. PubMed ID: 562231 [TBL] [Abstract][Full Text] [Related]
16. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease. Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094 [TBL] [Abstract][Full Text] [Related]
17. Long term effects of dichloromethylene diphosphonate in Paget's disease of bone. Delmas PD; Chapuy MC; Vignon E; Charhon S; Briancon D; Alexandre C; Edouard C; Meunier PJ J Clin Endocrinol Metab; 1982 Apr; 54(4):837-44. PubMed ID: 6460781 [TBL] [Abstract][Full Text] [Related]
18. [On the treatment of the osteodystrophia deformans (Paget's disease) with synthetic salmon calcitonin (author's transl)]. Trzenschik K; Schmidt UJ; Abendroth K; Ansorg H; Graner H; Lindenhayn K; Schramm G; Kalbe I Z Alternsforsch; 1978; 33(5):441-51. PubMed ID: 570764 [TBL] [Abstract][Full Text] [Related]
19. Chronic treatment of Paget's disease of bone with synthetic human calcitonin. Lang R; Milkman M; Jensen PS; Vignery AM Yale J Biol Med; 1981; 54(5):355-65. PubMed ID: 7336766 [TBL] [Abstract][Full Text] [Related]
20. Aminohexane diphosphonate in the treatment of Paget's disease of bone. Atkins RM; Yates AJ; Gray RE; Urwin GH; Hamdy NA; Beneton MN; Rosini S; Kanis JA J Bone Miner Res; 1987 Aug; 2(4):273-9. PubMed ID: 3455614 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]